Allogene Therapeutics to Present at Upcoming Investor Conferences

jueves, 5 de febrero de 2026, 1:44 pm ET1 min de lectura
ALLO--

Allogene Therapeutics, a clinical-stage biotechnology company, will participate in two upcoming investor conferences. The company is focused on developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Allogene's participation in these conferences aims to showcase its progress and potential in the field of allogeneic CAR T therapy.

Allogene Therapeutics to Present at Upcoming Investor Conferences

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios